Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: And some still think S&L is our enemy....

You state that per the 10-K, there were approx 29M warrants left.  Where do you get that info.  The way I read the SEC Filings, they list Lincoln's position (S&L are combined), and then they always have a footnote similar to this:

Includes 23,845,100 shares issuable upon the exercise of warrants. The documents governing Lincoln Ventures, LLC’s (“Lincoln”) warrants contain a provision prohibiting Lincoln from exercising warrants for shares of Common Stock if doing so would result in it and its affiliates beneficially owning shares of Common Stock representing more than 9.99% of the outstanding shares of Common Stock as determined under Section 13(d) of the Securities Exchange Act of 1934. If Swartz Private Equity LLC (“Swartz”) were determined to be an affiliate of Lincoln, then Lincoln’s exercisable warrant position would be reduced to the extent necessary to limit the combined beneficial ownership of Lincoln and Swartz to 9.99% of the Company’s outstanding Common Stock.

So per that footnote, Lincoln's position INCLUDES the exercisable warrants already.  All the rest of the SEC filings like the S13G all suggest that S&L continue to HOLD these shares.  Also as beneficial owners, they would have to report their sells would they not?  I know at least each year, they have to file an S13G filing indicating their holdings, and per their last filing, they hold over 38M shares.

Why do you and others continue to insist that S&L is selling.  Where do you pull that assumption from?  

Share
New Message
Please login to post a reply